Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.

about

Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.

Item

http://www.wikidata.org/entity/Q38617817

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Body mass index and clinical r ...... nts with rheumatoid arthritis.

@en

type

Item

label

Body mass index and clinical r ...... nts with rheumatoid arthritis.

@en

prefLabel

Body mass index and clinical r ...... nts with rheumatoid arthritis.

@en

P1476

Body mass index and clinical r ...... nts with rheumatoid arthritis.

@en

P2093

Bindu Murthy

http://www.w3.org/2001/XMLSchema#string

Eduardo Mysler

http://www.w3.org/2001/XMLSchema#string

Julia Heitzmann

http://www.w3.org/2001/XMLSchema#string

June Ye

http://www.w3.org/2001/XMLSchema#string

Manuela Le Bars

http://www.w3.org/2001/XMLSchema#string

Maria-Antonietta D'Agostino

http://www.w3.org/2001/XMLSchema#string

Radu Vadanici

http://www.w3.org/2001/XMLSchema#string

Rieke Alten

http://www.w3.org/2001/XMLSchema#string

P2860

EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.

Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.

Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study.

Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases).

Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.

Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.

The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.

Greater body mass independently predicts less radiographic progression on X-ray and MRI over 1-2 years.

Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study.

A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumato

P304

2655-2665

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10067-017-3788-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gianfranco Ferraccioli

Maria Antonietta D'Agostino

P577

2017-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28822046

http://www.w3.org/2001/XMLSchema#string

P932

5681604

http://www.w3.org/2001/XMLSchema#string